Loading...
XNAS
ICUCW
Market cap6mUSD
Oct 30, Last price  
0.01USD
1D
-34.73%
1Q
-43.52%
IPO
-90.09%
Name

SeaStar Medical Holding Corp

Chart & performance

D1W1MN
XNAS:ICUCW chart

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Based in Denver, Colorado, SeaStar Medical Holding Corporation operates as a medical device company. Its primary mission is to develop innovative therapies and services designed to combat hyperinflammation and cytokine storm, particularly in critically ill individuals. The company specializes in advancing and bringing to market extracorporeal treatments. These therapies are engineered to specifically target the immune "effector cells" that fuel widespread systemic inflammation, which is known to cause direct tissue damage and unleash a cascade of pro-inflammatory cytokines, leading to dysregulated immune responses. SeaStar Medical's product pipeline extends across diverse therapeutic domains. These include both pediatric and adult acute kidney injury, particularly when patients are undergoing continuous renal replacement therapy (CRRT); cardiorenal syndrome observed in cases of congestive heart failure, whether or not an LVAD is present; myocardial stunning associated with end-stage renal disease; and hepatorenal syndrome.

Key people

Jennifer Baird
Independent Chairman of the Board · since 2025
Michael Messinger
Chief Financial Officer · since 2025
Kevin Chung
Chief Medical Officer · since 2022
John Neuman
Director · since 2024
Eric Schlorff
Chief Executive Officer, Treasurer, Director · since 2025
Allan Collins
Independent Director · since 2021
Kenneth Van Heel
Independent Director · since 2021
Bernadette Vincent
Independent Director · since 2024
IPO date
Jan 26, 2021
Employees
9
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT